.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Rizatriptan benzoate - Generic Drug Details

« Back to Dashboard
Rizatriptan benzoate is the generic ingredient in three branded drugs marketed by Glenmark Generics, Cipla Ltd, Sandoz, Jubilant Generics, Invagen Pharms, Apotex Inc, Macleods Pharms Ltd, Nostrum Labs Inc, Aurobindo Pharma Ltd, Teva Pharms, Merck, Alkem Labs Ltd, Mylan Pharms Inc, Natco Pharma Ltd, and Emcure Pharms Ltd, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for rizatriptan benzoate. Twenty-seven suppliers are listed for this compound.

Summary for Generic Name: rizatriptan benzoate

Tradenames:3
Patents:0
Applicants:15
NDAs:24
Drug Master File Entries: see list22
Suppliers / Packaging: see list27
Therapeutic Class:Antimigraine Agents

Pharmacology for Ingredient: rizatriptan benzoate

Clinical Trials for: rizatriptan benzoate

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Natco Pharma Ltd
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL200482-002Dec 31, 2012RXNo<disabled><disabled>
Emcure Pharms Ltd
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL204090-002Nov 26, 2013RXNo<disabled><disabled>
Emcure Pharms Ltd
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL204090-001Nov 26, 2013RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rizatriptan benzoate

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-002Jun 29, 19984,305,502<disabled>
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-002Jun 29, 19985,457,895*PED<disabled>
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-001Jun 29, 19985,298,520*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc